JP2009515831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515831A5 JP2009515831A5 JP2008537233A JP2008537233A JP2009515831A5 JP 2009515831 A5 JP2009515831 A5 JP 2009515831A5 JP 2008537233 A JP2008537233 A JP 2008537233A JP 2008537233 A JP2008537233 A JP 2008537233A JP 2009515831 A5 JP2009515831 A5 JP 2009515831A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antigens
- immunogenic composition
- combination
- pestis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 370
- 102000036639 antigens Human genes 0.000 claims 370
- 108091007433 antigens Proteins 0.000 claims 370
- 230000002163 immunogen Effects 0.000 claims 54
- 241000124008 Mammalia Species 0.000 claims 9
- 230000028993 immune response Effects 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 101100421109 Yersinia pestis secM gene Proteins 0.000 claims 5
- 101100493693 Yersinia pestis bamC gene Proteins 0.000 claims 4
- 101100116909 Yersinia pestis djlA gene Proteins 0.000 claims 4
- 101100294224 Yersinia pestis nlpI gene Proteins 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 101100381447 Yersinia pestis bamA gene Proteins 0.000 claims 3
- 101100440427 Yersinia pestis coaE gene Proteins 0.000 claims 3
- 101100281900 Yersinia pestis fyuA gene Proteins 0.000 claims 3
- 101100220525 Yersinia pestis groEL gene Proteins 0.000 claims 3
- 101100188657 Yersinia pestis ompA gene Proteins 0.000 claims 3
- 101100060882 Yersinia pestis pla gene Proteins 0.000 claims 3
- 101100475179 Yersinia pestis rpsC gene Proteins 0.000 claims 3
- 101100093726 Yersinia pestis rpsD gene Proteins 0.000 claims 3
- 101100256513 Yersinia pestis secB gene Proteins 0.000 claims 3
- 101100478915 Yersinia pestis surA gene Proteins 0.000 claims 3
- 101100118435 Yersinia pestis tufA gene Proteins 0.000 claims 3
- -1 YPO0501 Proteins 0.000 claims 2
- 101100170819 Yersinia pestis dnaK gene Proteins 0.000 claims 2
- 101100064180 Yersinia pestis dsbA gene Proteins 0.000 claims 2
- 101100393774 Yersinia pestis hemL gene Proteins 0.000 claims 2
- 101100126385 Yersinia pestis ispD gene Proteins 0.000 claims 2
- 101100472136 Yersinia pestis rplI gene Proteins 0.000 claims 2
- 101100365859 Yersinia pestis skp gene Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 101100370051 Yersinia pestis tolB gene Proteins 0.000 claims 1
- 101100207359 Yersinia pestis tpx gene Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73018205P | 2005-10-25 | 2005-10-25 | |
| US81783806P | 2006-06-30 | 2006-06-30 | |
| PCT/IB2006/003843 WO2007049155A2 (en) | 2005-10-25 | 2006-10-25 | Compositions comprising yersinia pestis antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515831A JP2009515831A (ja) | 2009-04-16 |
| JP2009515831A5 true JP2009515831A5 (enExample) | 2010-11-11 |
Family
ID=37968196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008537233A Pending JP2009515831A (ja) | 2005-10-25 | 2006-10-25 | ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7776336B2 (enExample) |
| EP (1) | EP1954306A2 (enExample) |
| JP (1) | JP2009515831A (enExample) |
| AU (1) | AU2006307602A1 (enExample) |
| CA (1) | CA2627302A1 (enExample) |
| WO (1) | WO2007049155A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| GB0525213D0 (en) * | 2005-12-12 | 2006-01-18 | Secr Defence | Vaccine |
| US10174100B1 (en) * | 2006-11-06 | 2019-01-08 | Microvax, Llc | Multivalent DNA composition for Yersinia pestis |
| GB0717187D0 (en) * | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
| US8722046B2 (en) * | 2009-04-08 | 2014-05-13 | The United States Of America As Represented By The Secretary Of The Army | Human monoclonal antibodies protective against bubonic plague |
| ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
| WO2011066454A1 (en) * | 2009-11-24 | 2011-06-03 | Inviragen, Inc. | Compositions, methods and uses for expression of enterobacterium-associated peptides |
| US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| US10286056B2 (en) | 2011-01-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with crystallisation inhibitors |
| US10357568B2 (en) | 2011-03-24 | 2019-07-23 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with phospholipids |
| RU2014104090A (ru) | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
| JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
| PT2750707T (pt) | 2011-08-31 | 2019-01-23 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para distribuição de arn que codifica imunogénio |
| AU2013320313B2 (en) | 2012-09-18 | 2018-07-12 | Glaxosmithkline Biologicals Sa | Outer membrane vesicles |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| ES2969956T3 (es) | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| CN112609013A (zh) * | 2021-01-12 | 2021-04-06 | 深圳市赛格诺生物科技有限公司 | 一种用于检测鼠疫耶尔森菌的荧光pcr试剂及方法 |
| US20240350410A1 (en) | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| US20250134824A1 (en) | 2021-08-16 | 2025-05-01 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0525213D0 (en) | 2005-12-12 | 2006-01-18 | Secr Defence | Vaccine |
-
2006
- 2006-10-25 EP EP06831828A patent/EP1954306A2/en not_active Withdrawn
- 2006-10-25 CA CA002627302A patent/CA2627302A1/en not_active Abandoned
- 2006-10-25 WO PCT/IB2006/003843 patent/WO2007049155A2/en not_active Ceased
- 2006-10-25 JP JP2008537233A patent/JP2009515831A/ja active Pending
- 2006-10-25 US US12/091,604 patent/US7776336B2/en not_active Expired - Fee Related
- 2006-10-25 AU AU2006307602A patent/AU2006307602A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501959A5 (enExample) | ||
| DE60329106D1 (de) | Ghrelin-träger-konjugate | |
| JP2010162023A5 (enExample) | ||
| JP2008529558A5 (enExample) | ||
| WO2006045796A3 (en) | Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof | |
| JP2009537143A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| WO2008057235A3 (en) | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | |
| WO2006063974A3 (en) | Il-15 antigen arrays and uses thereof | |
| JP2010524489A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| PL369863A1 (en) | Antigen arrays for treatment of allergic eosinophilic diseases | |
| AU2003246373A8 (en) | Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions | |
| JP2010532656A5 (enExample) | ||
| CN1610697A (zh) | 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途 | |
| JP2009520758A5 (enExample) | ||
| JP2011517938A5 (enExample) | ||
| WO2003039225A3 (en) | Antigen arrays comprising rankl for treatment of bone disease | |
| JP2015529677A5 (enExample) | ||
| Kovalenko et al. | Vaccine candidate against COVID-19 based on structurally modified plant virus as an adjuvant | |
| JP2010506926A5 (enExample) | ||
| JP2016528176A5 (enExample) | ||
| Nuzzaci et al. | In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine | |
| JP2006523185A5 (enExample) | ||
| WO2003059386A3 (en) | Prion protein carrier-conjugates |